Literature DB >> 28556912

Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.

W Li1, J Tu2, X Liu2, W Yang3.   

Abstract

Farnesyltransferase inhibitors have been tested in clinical trials for the treatment of tumours. In sepsis, the binding of programmed death 1 (PD-1) to programmed death ligand 1 (PD-L1) promotes lymphocyte apoptosis and decreases cytokine expression, thus affecting survival rates. The PD-1/PD-L1 pathway plays an important role in chronic viral infection, bacterial infection and sepsis. However, the precise immunosuppressive and anti-inflammatory functions of this pathway remain poorly understood. In our previous study, the induction of sepsis by caecal ligation and puncture (CLP) resulted in increased farnesyltransferase activity and farnesylated protein levels in the spleen relative to sham treatment. However, the effect of inhibition of farnesyltransferase activity on overall survival rates in patients with sepsis and the specific signalling pathway involved remain to be investigated. In this study, mice with CLP-induced sepsis were treated with farnesyltransferase inhibitor (FTI-277), and PD-L1 expression on septic spleen lymphocytes was examined. Flow cytometric analysis revealed that PD-L1 is expressed constitutively on lymphocytes and that PD-L1 protein expression was up-regulated strongly following CLP. FTI-277 down-regulated PD-L1 mRNA and protein expression on septic spleen lymphocytes in a dose-dependent manner. This effect was associated closely with nuclear factor kappa B (NF-κB). In addition, the significant damping effect of FTI-277 on the PD-L1 signal promoted interferon (IFN)-γ secretion, interleukin (IL)-2 production and splenocyte proliferation in response to anti-CD3+ CD28+ antibodies in mice. Furthermore, FTI-277 reduced spleen lymphocyte apoptosis in septic mice. Therefore, FTI-277 regulates spleen lymphocyte activity via the PD-L1 signalling pathway, with significant anti-inflammatory effects attributable to suppression of the NF-κB pathway. Farnesyltransferase represents a valuable therapeutic target for the treatment of sepsis.
© 2017 British Society for Immunology.

Entities:  

Keywords:  T cells; inflammation; molecular biology; transcription factors

Mesh:

Substances:

Year:  2017        PMID: 28556912      PMCID: PMC5588849          DOI: 10.1111/cei.12995

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  Normal responses to injury prevent systemic inflammation and can be immunosuppressive.

Authors:  R S Munford; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

Review 2.  The PD-1/PD-L1 pathway in human pathology.

Authors:  M Saresella; V Rainone; N M Al-Daghri; M Clerici; D Trabattoni
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

3.  B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.

Authors:  Junko Hori; Mingcong Wang; Megumi Miyashita; Keiko Tanemoto; Hiroshi Takahashi; Toshitada Takemori; Ko Okumura; Hideo Yagita; Miyuki Azuma
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

4.  Immunotherapy for sepsis--a new approach against an ancient foe.

Authors:  Richard S Hotchkiss; Steven Opal
Journal:  N Engl J Med       Date:  2010-07-01       Impact factor: 91.245

5.  Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib.

Authors:  Xiaohua Xue; Kuei-Tai A Lai; Jing-Feng Huang; Yin Gu; Lars Karlsson; Anne Fourie
Journal:  J Pharmacol Exp Ther       Date:  2005-12-13       Impact factor: 4.030

6.  Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance.

Authors:  Wen Yang; Marina Yamada; Yoshiaki Tamura; Kyungho Chang; Ji Mao; Lin Zou; Yan Feng; Kotaro Kida; Marielle Scherrer-Crosbie; Wei Chao; Fumito Ichinose; Yong-Ming Yu; Alan J Fischman; Ronald G Tompkins; Shanglong Yao; Masao Kaneki
Journal:  J Pharmacol Exp Ther       Date:  2011-08-26       Impact factor: 4.030

Review 7.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

8.  Lovastatin protects against experimental plague in mice.

Authors:  Saravanan Ayyadurai; Hubert Lepidi; Claude Nappez; Didier Raoult; Michel Drancourt
Journal:  PLoS One       Date:  2010-06-02       Impact factor: 3.240

9.  Nanohydroxyapatite incorporated electrospun polycaprolactone/polycaprolactone-polyethyleneglycol-polycaprolactone blend scaffold for bone tissue engineering applications.

Authors:  K R Remya; Jasmin Joseph; Susan Mani; Annie John; H K Varma; P Ramesh
Journal:  J Biomed Nanotechnol       Date:  2013-09       Impact factor: 4.099

10.  MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis.

Authors:  Matthew J Delano; Philip O Scumpia; Jason S Weinstein; Dominique Coco; Srinivas Nagaraj; Kindra M Kelly-Scumpia; Kerri A O'Malley; James L Wynn; Svetlana Antonenko; Samer Z Al-Quran; Ryan Swan; Chun-Shiang Chung; Mark A Atkinson; Reuben Ramphal; Dmitry I Gabrilovich; Wesley H Reeves; Alfred Ayala; Joseph Phillips; Drake Laface; Paul G Heyworth; Michael Clare-Salzler; Lyle L Moldawer
Journal:  J Exp Med       Date:  2007-06-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.